Use of COVID-19 Convalescent Plasma for Treatment of Symptomatic SARS-CoV-2 Infection at a Children’s Hospital: A Contribution to a Still Inadequate Body of Evidence

Use of COVID-19 Convalescent Plasma for Treatment of Symptomatic SARS-CoV-2 Infection at a Children’s Hospital: A Contribution to a Still Inadequate Body of Evidence

Data on COVID-19 convalescent plasma (CCP) safety and efficacy in children and young adults are limited. This single-center prospective, open-label trial evaluates CCP safety, neutralizing antibody kinetics, and outcomes in children and young adults with moderate/severe COVID-19 (April 2020–March 20...

Full description

Bibliographic Details
Main Authors: Antonio Arrieta, Alvaro E. Galvis, Stephanie Osborne, Tricia Morphew, Karen Imfeld, Claudia Enriquez, Janet Hoang, Marcia Swearingen, Delma J. Nieves, Negar Ashouri, Jasjit Singh, Diane Nugent
Format: Article
Language:English
Published: MDPI AG 2023-02-01
Series:Children
Subjects:
convalescent plasma
COVID-19 treatment
symptomatic SARS-CoV-2
pediatrics
Online Access:https://www.mdpi.com/2227-9067/10/2/350

Internet

https://www.mdpi.com/2227-9067/10/2/350

Similar Items